Here are five things to know:
1. The policy is effective June 15, 2016.
2. Geisinger Health Plan covers more than 500,000 people in Delaware, Maine, New Jersey, Pennsylvania and West Virginia.
3. The policy states other fusion products for sacroiliac joint fusion are “considered experimental/investigational or unproven and therefore not covered.”
4. The iFuse Implant System’s triangular shape is designed to provide 31 times the rotational resistance of a screw.
5. The product’s FDA clearance supports clinical study results for the system proving enhanced pain, patient function and quality of life.
More articles on spine:
Spine surgeon Dr. Michael Janssen helps powerboat racers make a splash back in the water — 4 highlights
NY Top Doc names Mount Sinai Health System’s Dr. Saad Chaudhary to esteemed list: 5 points
Irregular cerebrospinal fluid flow connected to idiopathic scoliosis — 6 takeaways
